文献速递腹部技术与安全MR

钆塞酸增强MRI中肝转移瘤肝胆期对比剂摄取模式能否预测胰腺导管腺癌预后

Hepatobiliary contrast uptake patterns on gadoxetic acid-enhanced MRI in liver metastases from pancreatic ductal adenocarcinoma: can it predict prognosis?
PubMed 文献 · Eur Radiol · 2020-08-12

回顾性纳入57例胰腺导管腺癌肝转移患者,评估钆塞酸增强MRI肝胆期(20分钟)转移灶对比剂摄取模式与总生存期的关系。199个转移灶中69%呈不均匀低信号、31%呈均匀低信号;不均匀组患者总生存期低于均匀组(平均48.5个月 vs 23.9个月,p=0.032)。肝胆期摄取模式可能是预测总生存期的影像生物标志物。

要点

  • 肝胆期(20分钟)转移灶呈不均匀低信号者占69%,均匀低信号者占31%。
  • 患者层面不均匀组总生存期低于均匀组(平均48.5个月 vs 23.9个月,p=0.032)。
  • 肝胆期摄取模式可能是预测胰腺导管腺癌肝转移患者总生存期的影像生物标志物。

核心结论

  • 肝胆期图像上肝转移灶的对比剂摄取模式可能作为预测胰腺导管腺癌肝转移患者总生存期的影像生物标志物。

研究设计与样本

  • 回顾性研究,经机构审查委员会批准并豁免书面知情同意,纳入57例胰腺导管腺癌肝转移患者(男30例、女27例,年龄46-92岁,平均64.9±9.2岁)。
  • 所有患者接受钆塞酸增强MR成像,于肝胆期(20分钟)图像上将转移灶内部形态分为不均匀或均匀低信号。
  • 患者层面分析时,同时存在两种模式结节的患者归入不均匀组。

关键影像表现/征象

  • 共分析199个肝转移灶,138个(69%)呈不均匀低信号,61个(31%)呈均匀低信号。
  • 18例患者(32%)仅见均匀低信号结节(均匀组),29例(51%)呈不均匀低信号,10例(17%)两种模式共存(归入不均匀组)。

诊断标准与关键数值

  • 肝胆期(20分钟)图像上转移灶内部形态分为不均匀低信号或均匀低信号。
  • 患者层面:仅均匀低信号结节者归为均匀组,不均匀低信号或两种模式共存者归为不均匀组。

临床应用与阅片要点

  • 阅片时可关注肝胆期(20分钟)肝转移灶是否呈均匀或不均匀低信号,并据此在患者层面分组。
  • 患者层面同时存在两种模式结节时归入不均匀组,该组总生存期低于均匀组(平均48.5个月 vs 23.9个月,p=0.032)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the relationship between the patterns of hepatobiliary phase (HBP) contrast uptake in liver metastases on gadoxetic acid-enhanced MR imaging and overall survival (OS) in patients with pancreatic ductal adenocarcinoma (PDAC).

METHODS: This retrospective study was approved by our institutional review board and written informed consent was waived. A total of 57 patients (30 men and 27 women; age range, 46-92 years; mean age, 64.9 ± 9.2 years) with PDAC and liver metastasis who had undergone gadoxetic acid-enhanced MR imaging were included. The internal morphologies of the nodules were classified as heterogeneous or homogeneous on HBP images (20 min). During patient-by-patient analysis, patients with both patterns of nodules were classified as belonging to the heterogeneous group. Kaplan-Meier analysis and log-rank test were conducted for univariate analysis and Cox proportional hazards regression was conducted for multivariate analysis to evaluate prognostic factors for OS in patients with PDAC and liver metastasis.

RESULTS: A total of 199 liver metastases were analyzed, among which 138 nodules (69%) demonstrated heterogeneous hypointensity, while 61 nodules (31%) demonstrated homogeneous hypointensity. Homogeneous hypointense nodules were encountered in 18 patients (32%; homogeneous group), heterogeneous in 29 patients (51%), and both patterns co-existed in 10 patients (17%; heterogeneous group). The heterogeneous group exhibited lower OS rates than the homogeneous group (mean OS, 48.5 months vs 23.9 months; p = 0.032).

CONCLUSIONS: Hepatobiliary contrast uptake pattern in liver metastasis on HBP images can be a potential imaging biomarker to predict OS in patients with PDAC and liver metastasis.

KEY POINTS: • Majority of the liver metastases were heterogeneous (69%) after gadoxetic acid-enhanced MR imaging. • Patients with heterogeneous hypointense nodules demonstrated lower overall survival rate. • Hepatobiliary contrast uptake pattern in liver metastasis is possibly associated with patients' prognosis.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Noda Y, Tochigi T, Baliyan V, et al. Hepatobiliary contrast uptake patterns on gadoxetic acid-enhanced MRI in liver metastases from pancreatic ductal adenocarcinoma: can it predict prognosis? Eur Radiol. 2020. PMID: 32783131. doi:10.1007/s00330-020-07115-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。